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Research in context 31 
Evidence before this study 32 
At the time of study initiation, past studies on PCV chemotherapy given after radiotherapy had failed 33 
to produce survival benefit in anaplastic oligodendrogliomas which was assumed to be a 34 
chemotherapy responsive disease. These studies also showed that 1p19q non-co-deleted tumors 35 
have a much worse prognosis compared to 1p/19q co-deleted tumors. At the same time, combined 36 
chemo-irradiation with temozolomide was shown to improve outcome in glioblastoma, which was 37 
considered a relatively chemo-therapy resistant disease. In this latter study, MGMT gene promoter 38 
methylation was found to be predictive of benefit to temozolomide; it remained unclear if both 39 
temozolomide given concurrent with and after (‘adjuvant’) radiotherapy were required to improve 40 
patient outcome.  41 
Added value of this study 42 
In a preplanned interim analysis this study shows that  12 cycles of adjuvant temozolomide given 43 
after radiotherapy improve overall and progression free survival in non-1p/19-codeleted anaplastic 44 
glioma.   45 
Implications of all the available evidence 46 
Standard of post-care for non-1p/19q1 codeleted anaplastic glioma should now be surgery followed 47 
by radiotherapy and 12 cycles of standard day 1-5 every 4 weeks temozolomide.  Ongoing molecular 48 
research within this trial will show whether IDH mutational status and MGMT promoter methylation 49 
can be used to identify the patients benefitting from temozolomide chemotherapy. Further follow-up 50 
of the CATNON trial is necessary to understand if temozolomide given concurrently with 51 
radiotherapy also improves survival.  52 
  53 
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 54 
Abstract Background, Methods, Findings, Interpretation, and Funding 55 
Background 56 
The role of temozolomide chemotherapy in newly-diagnosed anaplastic glioma without 1p/19q co-57 
deletion (‘non-co-deleted’) is unclear. The CATNON trial investigated the addition of a) concurrent 58 
and b) adjuvant temozolomide chemotherapy to 59.4 Gy of radiotherapy in adult patients with non-59 
codeleted anaplastic glioma .  60 
Methods   61 
In an open label study with a 2x2 factorial design patients with newly diagnosed non-co-deleted 62 
anaplastic glioma were randomized using minimization technique to either radiotherapy alone, 63 
radiotherapy followed by 12 cycles of adjuvant temozolomide 150-200 mg/m2 day 1-5 4-weekly, 64 
radiotherapy given concurrent with daily temozolomide 75 mg/m2, or radiotherapy with both 65 
concurrent and adjuvant temozolomide.   Patients were stratified for prognostic factors including 66 
centrally assessed O-6-methylguanine-DNA methyltransferase gene promoter methylation status.  67 
The primary endpoint was overall survival (OS) adjusted for stratification factors. The study design 68 
required 748 patients, with a planned interim analysis once 41% (219) of the required events had 69 
occurred and which required a p-value < 0.0084 to reject the null hypothesis.  (NCT00626990, EORTC 70 
26053-22054). 71 
Findings 72 
745 patients were included in the interim analysis.  The hazard ratio for OS for use of adjuvant 73 
temozolomide was 0.65 (99.145 % confidence interval: 0.45, 0.93) prompting the Independent Data 74 
Monitoring Committee to recommend early release of the data on adjuvant treatment. OS at 5 years 75 
was 55.9% with and 44.1% without adjuvant temozolomide.. Toxicity was mainly hematological and 76 
reversible. 77 
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Interpretation 78 
This is the first study to show a survival benefit of temozolomide chemotherapy after radiotherapy in 79 
newly diagnosed non-co-deleted anaplastic glioma. Further follow-up is required for analysis of the 80 
role of concurrent temozolomide and of molecular factors, in particular isocitrate dehydrogenase 81 
gene mutations.  82 
Funding 83 
Schering Plough/MSD supported this trial with an unrestricted grant and provided temozolomide; the 84 
trial was further supported by grants from the EORTC Cancer Research Fund, NRG Oncology 85 
Operations, NRG Oncology SDMC, and Cancer Australia. 86 
 87 
  88 
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Introduction 89 
The pivotal EORTC trial combining  temozolomide with radiotherapy in glioblastoma was the first to 90 
show a statistically significant and clinically meaningful benefit from adding chemotherapy to 91 
radiotherapy in glioma.1 That study also identified O6-ethylguaninemethyltransferase (MGMT) gene 92 
promoter methylation as a biomarker for increased activity of temozolomide.2 Concurrently, two 93 
trials in anaplastic oligodendroglioma investigating adjuvant chemotherapy with procarbazine, CCNU 94 
and vincristine (PCV) with radiotherapy failed to show a survival benefit at the time of their first 95 
analysis.3;4 However, these trials showed a major prognostic effect of the deletion of both the short 96 
arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), now known as 1p/19q co-97 
deletion (‘co-deleted’) and  associated previously with increased sensitivity to chemotherapy.5 Since 98 
tumors without 1p/19q co-deletion are generally less chemo-responsive, we asked whether 99 
combined chemo-radiotherapy with temozolomide would improve outcomes in non-co-deleted 100 
anaplastic gliomas, and also whether it was the concomitant (given during radiotherapy), or the 101 
adjuvant (given after conclusion of radiotherapy) temozolomide treatment which determined any 102 
survival benefit. These questions induced a trial which in a 2 x 2 factorial design randomized patients 103 
with non-co-deleted anaplastic glioma to four study arms: radiotherapy with or without concurrent 104 
temozolomide, and with or without adjuvant temozolomide. Shortly after the end of accrual a 105 
planned interim analysis was conducted. This analysis resulted in the recommendation by the 106 
Independent Data Monitoring Committee (IDMC) to immediately release the data on the addition of 107 
adjuvant temozolomide to radiotherapy. We now report on the outcome of adjuvant treatment 108 
based on the data and events the IDMC reviewed. 109 
  110 
Methods 111 
The CATNON intergroup trial was conducted in Australia (Cooperative trials Group for Neuro-112 
Oncology, COGNO), North America (NRG Oncology, Canadian Clinical Trials Group (CCTG) and Europe 113 
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(European Organization for Research and Treatment of Cancer (EORTC), Medical Research Council 114 
(MRC), NeuroOnkologische Arbeitsgemeinschaft der Deutschen Krebsgesellschaft (NOA)).  115 
Study design and participants 116 
The trial was a phase III, randomized, open-label, 2 x 2 factorial study involving patients with newly 117 
diagnosed anaplastic glioma without 1p/19q co-deletion. Previous surgery for low grade glioma was 118 
allowed, provided histological confirmation of an anaplastic tumor was obtained at progression. 119 
Patients were 18 years or older, with a WHO performance status 0-2, adequate hematological, renal 120 
and liver function, and on a stable or decreasing dose of corticosteroids. Treatment with other 121 
experimental agents was not allowed. Patients were required to start radiotherapy within 7 weeks of 122 
surgery and within 8 days of randomization. All patients gave written informed consent according to 123 
local, national and international guidelines. After stratification for institution, performance status (0 124 
vs >0), age (≤50 vs >50 years of age), 1p loss (yes vs no), the presence of oligodendroglial elements at 125 
microscopy (yes vs no) and MGMT promoter methylation status (methylated vs unmethylated vs 126 
indeterminate) patients were electronically randomized through the EORTC web-based ORTA system 127 
(http://www.eortc.org/investigators/).  128 
Tumor evaluation 129 
At patient registration, tumor material was submitted for pathology review, 1p/19q status 130 
determination, and assessment of MGMT promoter methylation status. Pathology review and central 131 
1p/19q determination were performed separately for North American and European/Australian 132 
patients. After central review of their local 1p/19q testing procedure, dedicated and experienced 133 
European centers were allowed to enroll patients based on the local histological and molecular 134 
diagnosis. For patients from centers requiring central pathology review, confirmation of the diagnosis 135 
of anaplastic glioma was required. For Europe and Australia, 1p/19q status was assessed using 136 
microsatellite analysis; in North America 1p/19q diagnostics were done with fluorescent in situ 137 
hybridization (FISH).6;7 MGMT promoter methylation was performed by two central laboratories 138 
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using quantitative PCR as previously described.8 If MGMT determination was not available in time to 139 
meet radiotherapy timelines, patients were randomized with an ‘indeterminate’ MGMT methylation 140 
status. 141 
Treatment 142 
Patients were 1:1:1:1 randomized using the minimization technique to radiotherapy alone, 143 
radiotherapy combined with temozolomide, radiotherapy followed by temozolomide, or 144 
radiotherapy combined with and followed by temozolomide. Radiotherapy consisted of 59.4 Gy in 33 145 
fractions of 1.8 Gy.  Whenever possible, target volume definition was based on co-registered pre- or 146 
(ideally) post-operative magnetic resonance imaging (MRI). From 2011 onwards, centers were 147 
allowed to use IMRT after additional quality assurance. The radiotherapy gross tumor volume (GTV) 148 
volume was the entire region of high signal intensity on T2 weighted MRI images or FLAIR sequences, 149 
the regions of enhancement, and the tumor resection cavity. A 1.5 to 2.0cm margin (edited for 150 
anatomical barriers) was added to the GTV for microscopic spread, and then 0.5-0.7cm for daily set-151 
up variability. Planning could be either by 3D-conformal radiotherapy or IMRT  and the plan had to 152 
conform to the ICRU 50/62 criteria for target volume coverage, dose normalization and 153 
homogeneity.9;10 Temozolomide was given daily during radiotherapy (including on non-154 
radiotherapy weekend days) at a dose of 75 mg/m2 for a maximum of 7 weeks. Adjuvant 155 
temozolomide started four weeks after completion of radiotherapy, for a maximum of 12 planned 156 
cycles. Temozolomide was given on days 1-5 every four weeks at a dose of 150 mg/m2 during the 157 
first cycle with dose escalation to 200 mg/m2 for subsequent cycles if no or only minimal toxicity was 158 
observed during the first cycle. Dose modifications were made as described elsewhere.1 Treatment 159 
at progression was left to the discretion of the treating physicians, but temozolomide was suggested 160 
in patients randomized to radiotherapy only. During concomitant chemo-radiotherapy, pneumocystis 161 
jirovecii prophylaxis was mandatory.  162 
Assessments 163 
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  164 
Patients were reviewed weekly during radiotherapy, four-weekly during adjuvant temozolomide 165 
treatment and every three months after the completion of all therapy.   Radiological assessment 166 
used MRI scans at baseline, four weeks after the end of radiotherapy and thereafter every three 167 
months until progression. Following progression, patients were followed up for survival. Progression 168 
was assessed using Macdonald’s criteria, incorporating steroid dose and with a description of the 169 
possibility of pseudoprogression.11 For non-enhancing tumors, progression was defined as a 25% 170 
increase  in tumor area  defined as the product of the two largest perpendicular diameters. Toxicities 171 
were scored using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI 172 
CTCAE) version 3.0.  For health-related quality of life (HRQoL) analysis, the EORTC QLQ-C30 and BN20 173 
questionnaires were used at baseline and all visits corresponding to MRI imaging.12 Cognition was 174 
assessed at the same time points using the MiniMental State Examination, and in dedicated centers 175 
with a more comprehensive test battery which was performed annually after the start of 176 
radiotherapy.13;14  HRQoL and Cognitive assessments will be reported separately. 177 
Statistics 178 
The study used a 2 by 2 factorial design with overall survival (OS) adjusted by the stratification factors 179 
as the primary endpoint. The study intended to answer two questions:  180 
QI: whether OS would be improved by concurrent temozolomide chemotherapy (comparing all 181 
patients receiving radiotherapy alone or radiotherapy followed by adjuvant temozolomide to all 182 
those receiving either radiotherapy and concurrent temozolomide or radiotherapy and concurrent 183 
followed by adjuvant temozolomide)  184 
QII: whether OS would be improved by adjuvant temozolomide chemotherapy (comparing all 185 
patients receiving radiotherapy alone and radiotherapy with concurrent temozolomide to all those 186 
receiving radiotherapy followed by adjuvant temozolomide or radiotherapy and concurrent followed 187 
by adjuvant temozolomide)  188 
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Survival was calculated from the date of randomization to the date of death from any cause. 189 
Secondary endpoints included univariate OS, PFS adjusted for stratification factors, landmark OS and 190 
PFS analyses, HRQoL outcomes, toxicity, and cognition. PFS was defined as the time from 191 
randomization to the date of first progression or death, whichever came first. For all time to event 192 
analyses, patients still alive and not having met the endpoint at the last follow-up visit were 193 
censored. The Kaplan Meier technique was used for the univariate estimates of OS and PFS. For the 194 
primary analysis of OS and PFS, the Cox proportional hazards model was fit with a question indicator 195 
variable (one for each question, QI and QII). Assuming a median survival of 24 months in patients 196 
receiving radiotherapy only and a risk reduction of 0.775 for both concurrent temozolomide and 197 
adjuvant temozolomide (two-sided logrank test), at an overall significance level of 5% and a power of 198 
83%, 523 events were needed and 748 patients were to be recruited. One interim analysis for 199 
efficacy was planned when 41% of the required events (n=219) had been observed. For this analysis, 200 
only the rejection of null hypothesis of no efficacy was considered for both questions; the nominal 201 
significance level for rejecting H0 was taken as 0.0084. To compensate for this interim look, 11 202 
additional events were needed for the final analysis (534 instead of 523).  203 
Primary analysis was on the intention-to-treat population defined as all randomized patients in the 204 
arm they were allocated to by randomization. Relative dose intensity (RDI) was calculated as the 205 
administered dose per time as delivered divided by the planned dose per planned time of delivery. In 206 
2011, the study was amended to include a prospective analysis of the efficacy results in relation to 207 
tumor IDH status and to allow iMRT after additional quality control for treatment delivery.  208 
Support and study analysis 209 
Schering Plough/Merck supported the study by an unrestricted grant and by the provision of 210 
temozolomide but had no role in the data collection, analysis, interpretation, writing of the 211 
manuscript or the decisions to submit . The study protocol was prepared by EORTC, the study 212 
database was developed, housed and analyzed by EORTC. TG, MvdB, BB and MW had access to all 213 
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data. All authors have reviewed and approved of the manuscript. No writing assistance was provided. 214 
AN, TG, BB and MvdB had the responsibility for the submission of the manuscript. 215 
  216 
Results  217 
Between December 4, 2007 and September 19, 2015 1407 patients were screened and 748 were 218 
randomized. The required number of events for the interim analysis was observed in May 2015. This 219 
report is based on all data up to May 31, 2015 (clinical cut-off date for the interim analysis), with a 220 
first database lock on August 31, 2015 for the report to the IDMC, and a second lock for the study 221 
report on May 12 2016.  At the time of the clinical cut-off date, 1400 patients had been registered 222 
and 745 randomized by 137 institutions in 12 countries (Figure 1). No significant imbalances in 223 
baseline characteristics were observed between the four treatment arms (Table 1). MGMT 224 
methylation status was available for 275 of 745 (37%) patients at randomization and for 550 of 745 225 
(74%) patients at the time of the interim analysis.  226 
Treatment 227 
All patients were treated according to the arm to which they were randomized. All except sixteen 228 
patients completed radiotherapy. Thirty patients did not start adjuvant treatment (figure 1), 21 of 229 
the 188 patients randomized to radiotherapy with concurrent temozolomide and 9 of the 185 230 
patients to radiotherapy alone.  RDI of concurrent temozolomide was more than 90% in 89% (312 231 
349)  of patients with sufficient treatment information available. The RDI in patients who completed 232 
adjuvant temozolomide was 92%; in 12% (31/262) of patients the RDI was below 70%. Sixty-four 233 
percent (167/262) of patients who completed adjuvant temozolomide had at least one cycle delayed: 234 
28% (74) for hematological toxicity, 6% (16) for non-hematological toxicity, 3% (8) for both and 47% 235 
(123) for non-drug related reasons.   236 
Toxicity 237 
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Treatment was generally well tolerated. The most frequent related toxicity was hematological 238 
(supplemental table 1), with 8-12% of patients in the temozolomide-containing arms experiencing 239 
grade 3 or 4 toxicities, most frequently thrombocytopenia (7–9%). Supplemental table 1 summarizes 240 
the most frequent non-hematological grade 3 and 4 toxicities, excluding neurological events. Apart 241 
from constitutional and gastrointestinal toxicities, most toxicities were judged unrelated. Grade 3 or 242 
4 increase in transaminases occurred in 1% of temozolomide treated patients (5:547). 243 
 Efficacy outcomes 244 
With a median follow-up of 27 months, 344 patients (46%) had progressed and 221 patients (30%) 245 
had died: 129 in the arms without adjuvant temozolomide and 92 in the adjuvant temozolomide 246 
arms. The HR [99.145 CI] for the primary endpoint of OS adjusted for stratification factors for the 247 
arms containing adjuvant temozolomide was 0.65 [0.45, 0.93] (Table 2). Figure 2a shows the 248 
univariate OS analysis (HR 0.67, 95% CI 0.51, 0.88). If the methylation status of tumors that became 249 
known after randomization are also considered, the HR [99.145 CI] for adjuvant temozolomide was 250 
0.651 [0.454, 0.934]. Age (under 50 or 50 years and older) was also a highly significant risk factor for 251 
survival (HR 4.0, [2.8, 5.7]).  In univariate analysis, PFS was also superior in patients receiving 252 
adjuvant temozolomide (Figure 2b, HR 0.62, 95% CI 0.50, 0.76]). Table 3 shows additional median 253 
and 5 year PFS and OS analyses.  254 
Treatment at progression 255 
In the non-adjuvant arms, 200 patients progressed, compared with 144 in the adjuvant arms. Details 256 
for treatment given at progression were available for 195 and 143 patents respectively 257 
(supplemental table 2). Of these 338 patients, 303 received some additional treatment, mostly 258 
chemotherapy. Any chemotherapy was given to 143 (73%) in the non-adjuvant and 89 (62%) in the 259 
adjuvant arm, with temozolomide or PCV chemotherapy respectively being given to 82 (42.1%) and 260 
19 (9.7%) in the non-adjuvant arms, and 31 (21.7%) and 20 (14.0%) in the adjuvant arms.  261 
Bevacizumab was administered to 44 patients (22.6%) in the non-adjuvant arms and 38 (26.6%) in 262 
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the adjuvant arms. (Radio)surgery was used in 18 (9%) of the non-adjuvant arm patients and 9 (6%)  263 
of the adjuvant arm patients. 264 
Discussion 265 
This planned interim analysis of the CATNON trial showed a statistically significant and clinically 266 
meaningful benefit of adjuvant temozolomide on OS and PFS in non-co-deleted anaplastic glioma, 267 
mandating immediate release of the results. With adjuvant temozolomide, median PFS increased 268 
from 19 to 42.8 months and five-year OS increased from 44% to 56% . The present data do not imply 269 
that concurrent temozolomide does not have a beneficial effect; they only indicate that the interim 270 
analysis for this comparison did not cross the predefined boundaries.  Of note, with 30% of patients 271 
having died and 46% having progressed, follow-up Is still immature and further follow-up is ongoing. 272 
Nevertheless, the HR observed in the interim analysis is striking, and passing the very strict statistical 273 
boundaries of the preplanned analysis.. With longer follow-up the survival curves diverge more , 274 
suggesting that with time the OS improvement is likely to increase. More follow-up is needed for 275 
both the answer to the concurrent question and for a more detailed OS analysis. 276 
This trial on a molecularly defined subgroup of anaplastic glioma is noteworthy for several reasons. 277 
By allowing only patients without co-deletion of 1p/19q, this is the first trial on glioma  which used 278 
molecular criteria for eligibility. This approach was induced by the worse outcome of 1p/19q non-co-279 
deleted tumors in the PCV trials on anaplastic oligodendroglioma.3;4 It is also the first trial in WHO 280 
grade II or III glioma with a radiotherapy only group that investigated the addition of temozolomide, 281 
rather than PCV, to radiotherapy.15-17 The toxicity profiles of PCV and single agent nitrosoureas are 282 
less favorable than that of temozolomide.18;19As a consequence, temozolomide has almost 283 
completely replaced PCV in clinical use. However, until now there has been no evidence supporting 284 
the activity temozolomide in the adjuvant setting in diffuse grade II or III glioma; the pivotal 285 
temozolomide trial investigated glioblastoma which represents at the molecular level an entirely 286 
different disease with as a rule no IDH mutations.1 Although CATNON recruited patients with a less 287 
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chemotherapy sensitive subset of anaplastic glioma compared to 1p/19q co-deleted glioma, 288 
temozolomide is clearly beneficial. Thirdly, prolonged follow-up was required to show an OS benefit 289 
in trials of adjuvant PCV in low grade glioma and anaplastic oligodendroglioma, with all three trials 290 
showing separation of survival curves only four to six years after randomization.15-17 Each of these 291 
trials was initially reported as negative for OS, before the impact of early adjuvant PCV on OS was 292 
demonstrated with longer follow-up. Strikingly, in the CATNON trial there is an early separation of 293 
the OS curves which was sufficiently large to be detected in the interim analysis  294 
By recruiting only patients without co-deletion of 1p/19q, this trial aimed at a molecularly defined 295 
subgroup of glioma patients ; since then further molecular research has resulted in new basic insight 296 
in glioma.  In 2008, key mutations were first identified in IDH1 and IDH2 genes, occurring in 70-80% 297 
of all grade II and III diffuse glioma. These mutations are associated with improved outcomes and are 298 
now the cornerstone of the WHO 2016 classification of glioma.20-24 In 2011 the study protocol was 299 
therefore amended to incorporate analyses of IDH mutation status; these molecular analyses of their 300 
predictive value for temozolomide efficacy are pending. In view of today’s emphasis on IDH 301 
mutations and the large metabolic differences between IDHmt and IDHwt tumors, future trials in 302 
grade II and III glioma should consider only either IDHmt or IDHwt tumors. 303 
The results of MGMT testing were not available for 60% of patients at the time of randomization, due 304 
to timelines issues with samples requiring both 1p/19q testing and MGMT testing in a limited 305 
timeframe. However, when considering the MGMT tests that became available post-randomization 306 
the study arms remained  well balanced for MGMT promoter methylation. We also note that the 307 
percentage of successfully tested tumors showing MGMT methylation (42%) is lower than 308 
anticipated, being within the range expected in glioblastoma.  This may be explained by the use in 309 
this trial of a PCR technique which was optimized for glioblastoma.8;25 To overcome both this 310 
technical issue and the still modest rate of successful MGMT determination, MGMT promoter 311 
methylation status testing will be repeated using a genome wide methylation platform.26;27 Both 312 
the presence of IDH mutations and MGMT promoter methylation have been proposed as predictive 313 
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factors for benefit to chemotherapy. 28  The results of this study that will have enrolled both patients 314 
with IDH mutant and with IDH wild type gliomas with an anticipated difference in prognosis and 315 
sensitivity to outcome will help to decide on this question.  316 
The interim analysis of the CATNON trial has shown a similar risk reduction (HR 0.65) in non-co-317 
deleted anaplastic glioma treated with adjuvant temozolomide to that from adjuvant PCV in the low 318 
grade glioma trial, with an overall HR of 0.59, and HR 0.73 for the subset of astrocytoma (less likely 319 
1p/19q co-deleted).17 Since the distinction between WHO grade II and III diffuse glioma is subjective 320 
and gradual and these tumors have similar molecular abnormalities, it seems reasonable to consider 321 
adjuvant temozolomide for patients with grade II non-co-deleted diffuse glioma.  Furthermore, four 322 
trials now show clear clinical benefits from adding chemotherapy to radiotherapy, whereas two trials 323 
in grade II and III glioma failed to show improved outcome with initial chemotherapy alone compared 324 
to initial radiotherapy alone.15-17;29;30 With the currently available data, it seems prudent to 325 
extrapolate that treatment with chemotherapy alone will deliver worse OS results compared to initial 326 
treatment with radiotherapy and adjuvant chemotherapy. Another issue relates to the use of 12 327 
cycles adjuvant treatment in this trial, whereas for glioblastoma 6 cycles of adjuvant temozolomide 328 
are advised. This duration of 12 cycles was chosen as half of the patients randomized to the adjuvant 329 
arm would not receive concurrent TMZ, and we specifically wanted sufficient TMZ exposure in the 330 
patients treated with TMZ in adjuvant setting alone. Lastly, the role of concurrent temozolomide 331 
remains to be clarified, at present no evidence based guidance can be given on this part of the 332 
treatment. While concurrent chemo-irradiation with temozolomide improves outcome in 333 
glioblastoma, outcome data on the individual parts of combined treatment (concurrent and 334 
adjuvant) in glioblastoma are lacking.1 Also, as opposed to the 12 months of adjuvant treatment in 335 
the CATNON trial, the pivotal glioblastoma trial used only 6 months adjuvant treatment. Of note, the 336 
use of concurrent temozolomide with radiation therapy may increase late neurotoxicity, which will 337 
especially be relevant in favorable prognosis patients.  338 
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To conclude, the preplanned interim analysis of the CATNON trial shows that 12 cycles of adjuvant 339 
temozolomide given after radiotherapy significantly improves OS in 1p/19q non-co-deleted 340 
anaplastic glioma and should now constitute standard care. Further follow-up and tissue studies are 341 
required to establish the efficacy of concurrent temozolomide chemotherapy and the impact of the 342 
molecular signature on outcome.  343 
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Table 1. Patient characteristics at the time of randomization, including the stratification factors (bolded).  391 
 Treatment arm  
 
RT 
(N=187) 
TMZ/RT 
(N=185) 
RT->TMZ 
(N=185) 
TMZ/RT->TMZ 
(N=188) 
Total 
(N=745) 
 N (%) N (%) N (%) N (%) N (%) 
Age  (years)                                                                                                                                                                                                                                        
 Median                                                                                                                                                                                                  42.2               43.2 39.9             42.8 42.2              
 Range                                                                                                                                                                                                   19.0 - 81.2        20.1 - 77.1 20.0 - 82.3 18.3 - 80.1        18.3 - 82.3        
 <50   years                                           132 (71)                                                                                           124 (67)                                                                                         129 (70)                                                              129 (69)                                                              514 (69)                               
 >50     years                                           55 (29)                                                                                          61 (33)                                                                                         56 (30)                                                              59 (31)                                                             231 (31)                                    
Presence of oligodendroglial elements (Yes vs No)                                        
 No oligo                                          144 (77)                                                                                           141 (76)                                                                                         143 (77)                                                              144 (77)                                                              572 (77)                               
 Oligo                                              43 (23)                                                                                          44 (24)                                                                                         42 (23)                                                              44 (23)                                                             173 (23)                                    
WHO Performance Status (>0 vs 0)                                                                                                                                                                                                                                                                                                                                                                                   
 PS 0                                              110 (59)                                                                                           109 (59)                                                                                         108 (58)                                                              112 (60)                                                              439 (59)                               
 PS >0                                              77 (41)                                                                                          76 (41)                                                                                         77 (42)                                                              76 (40)                                                             306 (41)                                    
Presence of 1p LOH (Yes vs No)                                                                                                                                                                                                                                                                                                                                                                                     
 1p no loss                                             173 (93)                                                                                           173 (94)                                                                                         171 (92)                                                              175 (93)                                                             692 (93)                                
 1p loss                                    14 (8)                                                                                           12 (7)                                                                                          14 (8)                                                              13 (7)                                                             53 (7)                               
Pre-randomization MGMT (Methylated vs Unmethylated vs Undetermined/invalid)         
 Methylated                                         29 (16)                                                                                          27 (14.6)                                    29 (16)                                             29 (15)                                                              114 (15)                                
 Unmethylated                                       40 (21)                                                                                          40 (21.6)                                    40 (22)                                             41 (22)                                                             161 (22)                                                              
 Undetermined/invalid                              118 (63)                                                                                          118 (63.8)                                 116 (63)                               118 (63)                                                             470 (63)                                
Post-randomization MGMT (Methylated vs Unmethylated vs Undetermined/invalid)            
 Methylated                                         60 (32)                                                                                          53 (29)                                                                                         66 (36)                                                              54 (29)                                                             233 (31)                                
 Unmethylated                                       80 (43)                                                                                          76 (41)                                                                                         76 (41)                                                              85 (45)                                                             317 (43)                               
 Undetermined/invalid                               47 (25)                                                                                          56 (30)                                                                                         43 (23)                                                              49 (26)                                                              195 (26)                               
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 Treatment arm  
 
RT 
(N=187) 
TMZ/RT 
(N=185) 
RT->TMZ 
(N=185) 
TMZ/RT->TMZ 
(N=188) 
Total 
(N=745) 
 N (%) N (%) N (%) N (%) N (%) 
Sex                                                                                                                                                                                                                                                                                                                                                                                                           
 male                                              107 (57)                                                                                           116 (63)                                                                                         102 (55)                                                              102 (54)                                                             427 (57)                              
 female                                             74 (40)                                                                                          65 (35)                                                                                         79 (43)                                                              79 (42)                                                              297 (40)                               
 Missing     6 (3)                                                                                           4 (2)                                                                                          4 (2)                                                              7 (4)                                                              21 (3)                               
Mini Mental State Evaluation                                                                                                                                                                                                                                
 Median                                                                                                                                                                                                  29 30           30 29               29              
 <27                    25 (13)                                                                                          21 (11)                                                                                         21 (11)                                                              24 (13)                                                              91 (12)                              
 >27                  138 (74)                                                                                           150 (81)                                                                                         145 (78)                                                              146 (78)                                                             579 (78)                              
 Missing                24 (13)                                                                                          14 (8)                                                                                        19 (10)                                                              18 (10)                                                              75 (10)                             
On corticosteroids at study entry                                                                                                                                                                                                                                                                                                                                                                  
 no                               131 (70)                                                                                           128 (69)                                                                                         128 (69)                                                              122 (65)                                                              509 (68)                              
 yes                     49 (26)                                                                                          54 (29)                                                                                         52 (28)                                                              58 (31)                                                             213 (29)                                
 Missing/unknown                           7 (4)                                                                                           3 (2)                                                                                          5 (3)                                                              8 (4)                                                             23 (3)                                            
Prior surgery for low grade tumor                                                                                                                                                                                                                                                                                                                                                                  
 no                                158 (85)                                                                                           161 (87)                                                                                         160 (87)                                                              154 (82)                                                             633 (85)                              
 yes                                23 (12)                                                                                          20 (11)                                                                                         21 (11)                                                              27 (14)                                                              91 (12)                              
 Missing                             6 (3)                                                                                           4 (2)                                                                                          4 (2.2)                                 7 (4)                              21 (3)                                                                  
Type of surgery                                                                                                                                                                                                                                                                                                                                                                               
 biopsy                             33 (18)                                                                                          41 (22)                                                                                         35 (19)                                                              40 (21)                                                             149 (20)                               
 partial removal                   100 (54)                                                                                          86 (47)                                 89 (48)                                                                  72 (38)                                                             347 (47)                               
 total removal                      48 (26)                                                                                          54 (29)                                                                                         57 (31)                                                              69 (37)                                                              228 (31)                               
  392 
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Table 2. Cox model of the primary endpoint, with the effect of adjuvant temozolomide adjusted by 393 
the stratification factors (and MGMT status at randomization).  394 
 395 
Parameter Pr > ChiSq 
Hazard 
Ratio (HR) 
99.145% HR 
Confidence Limits 
Adjuvant Temozolomide 0.0014 0.65 0.450, 0.926 
Age (>50 vs <50) <.0001 4.04 2.784, 5.867 
WHO Performance Status (>0 vs 0) 0.0273 1.36 0.943, 1.960 
Presence of 1p LOH (Yes vs No) 0.0572 1.56 0.844, 2.877 
Presence of oligodendroglial elements (Yes vs No) 0.2230 1.20 0.812, 1.762 
MGMT (Methylated vs Unmethylated) 0.0031 0.49 0.259, 0.925 
MGMT (Undetermined/invalid vs Unmethylated 0.1606 0.81 0.538, 1.207 
 396 
  397 
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77 3. Median (months) and 5-year OS and PFS (percentage) with 95% CI 398 
 399 
 Progression Free survival Overall Survival 
Adjuvant 
TMZ 
Events Median 
(months) 
% at 5-years Events Median (months) % alive  
at 5-years 
No 200 
19.0 
(14.4, 24.6) 
24.3 
(17.7, 31.6) 129 
41.10 
(36.6, 60.7) 44.1 (36.3, 51.6) 
Yes 144 
42.8 
(28.6, 60.6) 
43.1 
(35.0, 50.9) 92 Not reached 55.9 (47.2, 63.8) 
 400 
  401 
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Figure 1: CONSORT diagram at the time of interim analysis 402 
 403 
Figure 2 a, b. Overall survival (a) and Progression Free Survival (b) in patients treated with or without 404 
adjuvant temozolomide chemotherapy 405 
  406 
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